With the FDA's acceptance of Urogen's NDA and issuance of an 06/13/2025 PDUFA the clock is now ticking for FDA approval of ...
Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...
Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting - IRVINE, ...
Verywell Health on MSN3d
What to Expect From a Bladder UltrasoundA bladder ultrasound gives providers clues about how the bladder expands and holds urine. This article lists conditions ...
A recent study reveals that extended lymphadenectomy offers no survival advantage over standard lymphadenectomy for patients ...
1d
On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to ...
Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated ...
in muscle-invasive bladder cancer, MIBC. The publication is now available online and will be in a future print edition of Nature Medicine. The results were also presented at the Society for ...
In a phase 1b trial, treatment of patients with muscle-invasive bladder cancer with intravesical oncolytic virus cretostimogene grenadenorepvec in combination with nivolumab was safe and led to ...
To reduce colorectal cancer risk, being active in both the early morning and evening might provide greater benefits than ...
Other ones are UPIa, UPIb and UPIII IHC/RT-PCR 93.8–100% [98,101,98,102] Recurrence rate pN0 UPII+ 91 vs 5% pN0 UPII- (p < 0.001) [102] Around 25–30% of muscle invasive bladder cancer patients ...
Q3 2024 Earnings Call Transcript November 6, 2024 UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.55, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback